What is Viking Therapeutics?
Viking Therapeutics is a metabolic and endocrine therapeutics company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Metabolic and endocrine therapeutics
- Headquarters
- San Diego, CA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: VKTX
What is Viking Therapeutics?
Viking Therapeutics is a metabolic and endocrine therapeutics company headquartered in San Diego, CA.
Viking Therapeutics operates in metabolic and endocrine therapeutics and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around Obesity programs, VK2735, NASH/MASH programs, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Viking Therapeutics is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: VKTX, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Viking Therapeutics offer?
Viking Therapeutics's profile centers on Obesity programs, VK2735, NASH/MASH programs, Thyroid receptor beta agonists.
- Obesity programs· Metabolic and endocrine therapeutics
- VK2735· Metabolic and endocrine therapeutics
- NASH/MASH programs· Metabolic and endocrine therapeutics
- Thyroid receptor beta agonists· Metabolic and endocrine therapeutics
- Oral metabolic candidates· Metabolic and endocrine therapeutics
- Clinical development· Metabolic and endocrine therapeutics
How does Viking Therapeutics make money?
Viking Therapeutics makes money through commercial activity tied to metabolic and endocrine therapeutics.
Viking Therapeutics monetizes through the commercial model common to metabolic and endocrine therapeutics: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Viking Therapeutics?
Viking Therapeutics's named executives should be verified on the official leadership or investor-relations page before outreach.
- Viking Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Viking Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Viking Therapeutics technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Viking Therapeutics's leadership?
Viking Therapeutics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.vikingtherapeutics.com- Viking Therapeutics investor relationsInvestor relations / corporate contactcontact via https://www.vikingtherapeutics.com
- Viking Therapeutics sales or partnershipsCommercial contact routecontact via https://www.vikingtherapeutics.com
- Viking Therapeutics media relationsMedia or communications contact routecontact via https://www.vikingtherapeutics.com
How is Viking Therapeutics funded?
Viking Therapeutics's current status is Public company; Nasdaq: VKTX.
Viking Therapeutics's current capital profile is best understood through its current status: Public company; Nasdaq: VKTX. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Viking Therapeutics get here?
Viking Therapeutics's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingViking Therapeutics is foundedThe company begins building in metabolic and endocrine therapeutics.
- Scale-upCommercial footprint expandsViking Therapeutics broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: VKTXOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Viking Therapeutics's competitors?
Viking Therapeutics competes with larger platform incumbents and focused specialists in metabolic and endocrine therapeutics.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Viking Therapeutics — frequently asked questions
